Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis. - Wikidata - awgldk - TriplyDB

Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis.

Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis.

http://www.wikidata.org/entity/Q34161200

about

Bone as an endocrine organ Partial agonist, telmisartan, maintains PPARγ serine 112 phosphorylation, and does not affect osteoblast differentiation and bone mass The Bone Marrow-Derived Stromal Cells: Commitment and Regulation of Adipogenesis Recognizing and treating secondary osteoporosis Medical Management of Diabesity: Do We Have Realistic Targets?Osteoporosis piece of multi-morbidity puzzle in geriatric care.Diabetes, bone and glucose-lowering agents: basic biology.Bone marrow fat has brown adipose tissue characteristics, which are attenuated with aging and diabetes.Minireview: nuclear receptor regulation of osteoclast and bone remodeling.Republished: Non-alcoholic fatty liver disease: a practical approach to treatment.Thiazolidinediones on PPARγ: The Roles in Bone Remodeling.Management of diabetes across the course of disease: minimizing obesity-associated complications Glycemic Control with Thiazolidinedione Is Associated with Fracture of T2DM Patients.Fracture incidence and risk of osteoporosis in female type 2 diabetic patients in Korea.Pathophysiological role of enhanced bone marrow adipogenesis in diabetic complications.Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs.Rheumatic manifestations in diabetic patients Reciprocal Control of Osteogenic and Adipogenic Differentiation by ERK/MAP Kinase Phosphorylation of Runx2 and PPARγ Transcription Factors.Glucose and low-density lipoprotein cholesterol lowering in elderly patients with type 2 diabetes: focus on combination therapy with colesevelam HCl.Safety of Anti-Diabetic Therapies on Bone.Rosiglitazone inhibits bone regeneration and causes significant accumulation of fat at sites of new bone formation.Hyperglycemia induces endoplasmic reticulum stress-dependent CHOP expression in osteoblasts.VCE-003.2, a novel cannabigerol derivative, enhances neuronal progenitor cell survival and alleviates symptomatology in murine models of Huntington's disease.Causes, consequences, and treatment of osteoporosis in men.The anti-diabetic drug metformin does not affect bone mass in vivo or fracture healing.All-trans retinoic acid shifts rosiglitazone-induced adipogenic differentiation to osteogenic differentiation in mouse embryonic fibroblasts.The effects of rosiglitazone on osteoblastic differentiation, osteoclast formation and bone resorption.Fracture Risk in Type 2 Diabetes: Current Perspectives and Gender Differences Melatonin-micronutrients Osteopenia Treatment Study (MOTS): a translational study assessing melatonin, strontium (citrate), vitamin D3 and vitamin K2 (MK7) on bone density, bone marker turnover and health related quality of life in postmenopausal os Transitioning from inpatient to outpatient therapy in patients with in-hospital hyperglycemia.Potential drug interactions associated with treatments for type 2 diabetes and its comorbidities: a clinical pharmacology review.Diabetes and fracture healing: the skeletal effects of diabetic drugs.There are many potential medical therapies for atraumatic osteonecrosis.Diabetes mellitus and inflammatory pulpal and periapical disease: a review.Diabetes mellitus and osteoporosis.Adipocytes and the regulation of bone remodeling: a balancing act.Revisiting weight reduction and management in the diabetic patient: Novel therapies provide new strategies.Review article: new treatments in non-alcoholic fatty liver disease.Non-alcoholic fatty liver disease in 2016.Vitamin D Level Between Calcium-Phosphorus Homeostasis and Immune System: New Perspective in Osteoporosis.

P2860

Q27010173-81CD9FC0-D10C-42A3-8ADC-387F5FA8EA2F Q27334866-D9C9F2F4-1E63-44EF-9D63-715E5BC0AC28 Q28078585-B99EF62C-0693-418E-940A-06A802CF31F8 Q28270738-B57D2041-3B8F-4FB5-B675-0EFF72C90DF5 Q30238940-909215B6-805C-4CC8-8974-2F5E43639ABD Q33351754-A7860A8E-D1DC-421F-8301-B0990F278D98 Q33843692-6754788D-D857-42F9-BF23-C0F1F926B57A Q34197048-F0A6AB40-9EC6-412E-9CF3-8EDCC04A9BE5 Q35054970-92E7B0EF-241A-4DD9-9A82-CC9138B5E4CE Q35135556-1102552E-61F8-44D8-838B-049E92D95EFF Q35496098-289167F9-4F96-44AA-B268-88C5E4FF4608 Q35574560-4C2D0C4E-4F45-4C18-A018-E496BB5C73AD Q35759258-8275A67F-E358-485D-B3CF-C77D8B1DD0A1 Q35911081-76BDB809-244D-4103-8531-8788C024EE38 Q35998796-4A438C88-C531-4C2B-8B32-77142E18321D Q36297873-1377FEC7-1161-4E7F-B54A-BEA87190C725 Q36299797-05B1FB9C-9374-463F-B331-A22245607D39 Q36558095-CE089B5C-84B6-4DC3-9A67-8B6366D553B7 Q36649815-4FF965A3-F7DC-4B57-BE0C-55274C532A5B Q36716222-5ED6F333-353E-411D-9C98-0A2FFE47702D Q36779975-F20887B9-7F2B-4C56-A2EA-85F9654CA748 Q36900471-EA1D060D-38BE-4FB4-9808-274FB4537FA8 Q37105051-2C622362-2463-420F-848E-D5635BDC1930 Q37134718-591AB800-5579-4D00-BBC1-8744A268BC2F Q37182800-CEBC1919-D686-4718-891D-CAE2B988A6D2 Q37426679-BAA7255A-6AA2-45CA-B8C2-0DEC15A4E1B3 Q37461510-8AE7FE56-E20E-4588-8B3E-CF31B69153C6 Q37511845-3BFA45C8-0C3A-4957-B0A6-26C3D8C7BF85 Q37643521-25738027-779D-4EBF-B213-A699666DC378 Q37953155-574EC708-8B00-44F6-AE51-54668774F7F0 Q37964751-E1C82A75-1528-4904-AC29-DF895CC1EA51 Q37965266-E6E21FCB-1453-42EA-B9DB-B33339CF1E2D Q38049949-B9A4703D-7F9B-4AD7-9511-295AAA91FB39 Q38084724-D2B0D9AD-D46B-4A9F-BE0D-A970C64109A8 Q38087556-974EC286-F043-4E3D-A86E-CE31C39F68D2 Q38150258-BF570DD5-8DBE-4857-AAC8-55AE2082CED3 Q38442816-786EA494-F058-4F69-9083-DCF042ABED1B Q38662765-DC68E3E5-0041-4BA3-9B86-8FBE4C9C86C7 Q38932554-FC6A9D0A-727F-4548-BFD2-651B9DF5DD15 Q38979293-53F49D3B-C7DE-4612-84AE-0DF4620CF6D1

P2860

Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis.

http://www.wikidata.org/entity/Q34161200

description

2010 nî lūn-bûn

@nan

2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis.

@ast

Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis.

@en

Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis.

@nl

type

label

Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis.

@ast

Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis.

@en

Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis.

@nl

prefLabel

Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis.

@ast

Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis.

@en

Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis.

@nl

P1433

Q34161200-7A41C249-EA6D-47A6-93C5-330A66E9CDF8

P1476

Q34161200-8B144402-7D6C-4B99-B69D-14E61449D123

P2093

Q34161200-7C146B26-5776-44E8-99C7-51A9C07FA3A1

P2860

Q34161200-0437780D-6318-49BF-A0B2-973B00869D08

Q34161200-0D69D9A8-FB4F-4364-8B0C-11B6BB4B10D3

Q34161200-0D6FF1FB-45EF-4D2C-BE4A-2273B2736DAD

Q34161200-18581B72-DFC6-4690-AC79-E33779D2D892

Q34161200-1B4DCEB6-6686-4071-886F-3EE73E8C1F05

Q34161200-2073C2B8-B68F-4700-BDB6-49897F288A1E

Q34161200-231FFA18-3946-475D-987C-7E7DB8CEB76F

Q34161200-2653D29F-3D9A-4249-A3F4-DAB4C7D0C90B

Q34161200-3737213F-20A5-4C43-BE2C-10608ED5486E

Q34161200-3F42251A-BB44-4953-8D8A-6F7A0414081E

P2888

Q34161200-C00E544A-89EF-4196-A29D-2D06638F32C1

P304

Q34161200-1F141F68-1817-469B-8B23-A4AD32E07A1D

P31

Q34161200-064B3C46-6967-4E92-B66E-A17238CAE2B6

Q34161200-6BD7C4A1-0565-41E5-8A11-800CE11E9F0A

P356

Q34161200-5A2C9377-73F1-44A4-976C-9997A3AD29C4

P433

Q34161200-EF2581D1-41ED-40B3-BE66-9D2ACD4FBB62

P478

Q34161200-5A26566C-5622-4A20-AAA6-A8560C3BF822

P577

Q34161200-4C78A675-9CC9-4FBB-A879-BFA695F8D1F5

P5875

Q34161200-8C3990EA-2303-44A1-9C29-C88649A09604

P6179

Q34161200-D5636A81-50F0-4831-AAC8-8C6EAC2EDE9C

P698

Q34161200-7934EDBE-0EE9-4718-BA29-6DCA4F8FF63D

P921

Q34161200-0EFF9956-DBA8-4006-8A0E-9A45A278D193

Q34161200-6A1B6AC4-4878-4BCF-BD93-D0C2520889B6

Q34161200-B4E2E913-F2AB-42BF-86B3-0A87175BE54C

Q34161200-D73336F1-A0BC-4B23-81D3-EE8CB411BE35

Q34161200-FCFB7398-0341-4E51-A25E-33B401AF3972

P932

Q34161200-48A7BF77-3D53-4168-8EC6-9910FF8C8864

P356

S11914-010-0027-Y

P1433

Current osteoporosis reports

P1476

Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis.

@en

P2093

Beata Lecka-Czernik

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis

Fat and beyond: the diverse biology of PPARgamma

Genetic regulation of osteoclast development and function

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

The risk of fractures associated with thiazolidinediones: a self-controlled case-series study

Oral antihyperglycemic therapy for type 2 diabetes mellitus.

Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus

Decreased osteoclastogenesis and high bone mass in mice with impaired insulin clearance due to liver-specific inactivation to CEACAM1

Thiazolidinediones.

P2888

s11914-010-0027-y

P304

178-184

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11914-010-0027-Y

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2010-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

46108944

http://www.w3.org/2001/XMLSchema#string

P6179

1011800527

http://www.w3.org/2001/XMLSchema#string

P698

20809203

http://www.w3.org/2001/XMLSchema#string

P921

heterocyclic compound

type-2 diabetes

maturity-onset diabetes of the young

P932

2947013

http://www.w3.org/2001/XMLSchema#string